NEWSROOM

Epidemiologic Solutions Corporation (ESC), an IRS approved, qualified public charity, announces its funding for its “pain-free-veterans” initiative

 

Westlake, LA, April 14, 2021 – –  Epidemiologic Solutions Corporation (ESC), a public charity qualified by the Internal Revenue Service pursuant to Section 501(c)(3) commits not less than $200,000 of funding to Gold River Productions Services (OTC Pink: GRPS) for its development of PainplexTM an all-herbal extraction developed by Gold River Productions Services (GRPS) and other formulations.  This will be part of the “Relief Kit,” which will include products from both GRPS and Halberd Corporation (OTC Pink: HALB) designed to alleviate moderate to severe discomfort without opioids or other potentially harmful and addictive drug.  The kit and products will be available free of charge to veterans in need. Such veterans will be encouraged to provide feedback about “Relief Kit.”

William Hartman, CEO of HALB states, “This is a huge step forward in providing relief to our veterans who have suffered too much for too long without relief.  Halberd’s hemp patch is designed to provide relief for up to four days, which I believe makes this product unique and will afford stand-alone or adjunctive help.”

Richard Goulding, M.D., Chairman of the Board of Gold River Productions (GRPS) has some further input.   “Opioid addiction is a very difficult problem and is particularly prevalent in veterans who often had to take narcotics for injuries.  PainplexTM is our proprietary formulation that is non-toxic and non-habit forming.  While we have seen overwhelming positive response to our Raspberry ReliefTM gummies, the complexity of relieving discomfort involves multiple approaches to the problem.  PainplexTM will be our first commercially available herbal blend formulated by Dr. Bruce Bond, who has been involved with its creation for over 25 years having perfected the compounding with a large volume of patients.  While we have discounted the product to the charitable foundation, this still represents income to the company and allows us an incredible opportunity to have actual product created and available for sale.  But even more important is what Epidemiologic Solutions is able to do for our veterans.  With the implementation of PainplexTM this not only launches our nutraceutical products line, but allows us to help fund Epidemiologic Solutions in perpetuity with a percentage of our sales proceeds going back to the charity.  In essence, this launches the catalyst to continue our efforts to support veterans as they deserve to be supported.  Supplying veterans with non-toxic solutions to sleep, anxiety and pain has always been our goal and we are thrilled to contribute in this small way to their comfort and health.”

Dr. Bruce Bond, Chief Products Development officer of Gold River Productions states, “We are so thrilled to be able to help veterans with their principal medical issues.  This collaboration with ESC is an amazing endeavor.  We hope to provide a “Relief Kit.”  This will be a package designed to cover all aspects of discomfort, and will include, but not be limited to our CBG gummies, and some new products we have seen astounding results with.  In addition to the Hemp patch of Halberd’s, which is an amazing and long-lasting product, we hope to be able to offer this kit to our investors first, on a limited basis, and then the public.  In addition to the foregoing, we have 16 nutraceutical formulations in various stages of R&D that will be developed in sequence.  They cover a number of concerns from male stamina to energy and more.  This has been developed from over 25 years of clinical practice and years in the nutraceutical industry.  Basically, with proper extraction and combinations, we can achieve efficacy and real value for our patients.”

*Note:  These products not been evaluated by the FDA.  We make no claims as that these or any of our products are cures or treatments for any disease.

We welcome any donations, which can be done by visiting our website at:

http://epidemiologicsolutions.com/

Contribution is tax-deductible in accordance with the provisions of Internal Revenue Code Sections 26 U.S. Code § 170 and 501©(3). We also welcome suggestions.

DISCLAIMER: ESC seeks donations. Payments to ESC do not constitute an investment; there is no quid pro quo. By making a donation, one does not receive any kind of equity or nonequity benefit that specifically accrues to the donor. Instead, we only hope that you and others will help to make the world a better place.

CONTACT:

Epidemiologic Solutions Corporation

http://epidemiologicsolutions.com/

info@EpidemiologicSolutions.com

Twitter: @escscientific

About Gold River Productions Inc., GRPS: 

Gold River will focus on market-targeted products including, but not limited to rare cannabinoids and effective products where a particular need is identified.  Products for pain relief, sleep, etc. that will be distributed through convenience stores, independent pharmacies and some proprietary products through physicians.

CONTACT: Gold River Productions, Inc.

support@grpsinc.com

www.GRPSInc.com
@grpsinc

Twitter: @grpsinc

goldriversocialmedia@gmail.com

About Halberd Corporation.

Halberd Corporation (OTC-PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to several patent pending COVID-19 extracorporeal treatments:

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” and “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com

support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

The Company further cautions investors that the primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that the Company may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

 

Categories

Mcap MediaWire - Costumer Service